The 8 linked references in paper O. Barbarash L., V. Kashtalap V., О. Барбараш Л., В. Кашталап В. (2017) “КОНТРОЛЬ ЛИПИДОВ У ПАЦИЕНТОВ ПОСЛЕ ПЕРЕНЕСЕННОГО ИНФАРКТА МИОКАРДА — ЭФФЕКТИВНЫЙ ИНСТРУМЕНТ УПРАВЛЕНИЯ СЕРДЕЧНО-СОСУДИСТЫМ РИСКОМ // LIPID CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION - AN EFFECTIVE TOOL FOR MANAGING CARDIOVASCULAR RISKS” / spz:neicon:aterotromboz:y:2017:i:1:p:94-104

  1. Комплексные проблемы сердечно-сосудистых заболеваний, 2016, 2: 75-82. 3. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) European Heart Journal, 2016, 37: 2315-2381. doi: 10.1093/eurheartj/ehw106.
  2. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal,2016, 37: 267-315. doi: 10.1093/eurheartj/ehv320. (the paper at Socionet)
  3. Arnold SV, Kosiborod M, Tang F, Zhao Z, Maddox TM, McCollam PL, Birt J, Spertus JA. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation,2014, 129(12): 1303-9. doi: 10.1161/CIRCULATIONAHA.113.003589. Epub 2014 Feb 4.
  4. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Alirocumab for the treatment of hypercholesterolaemia. Expert Opin Biol Ther, 2017 Mar 9. doi: 10.1080/14712598.2017.1305354.
  5. du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacol Ther, 2017 Feb 14. pii: S0163-7258(17)30043-8. doi: 10.1016/j.pharmthera.2017.02.029.
  6. Koslik HJ, Meskimen AH, Golomb BA. Physicians’ Experiences as Patients with Statin Side Effects: A Case Series. Drug Saf Case Rep, 2017 Dec, 4(1): 3. doi: 10.1007/s40800-017-0045-0.
  7. Ridker PM, Mora S, Rose L, on Behalf of the JUPITER Trial Study Group. Per cent reduction in LDL cholesterol following high-intensity statin therapy: potential implicationsforguidelinesandfortheprescription of emerging lipid-lowering agents. European Heart Journal, 2016. doi: 10.1093/eurheartj/ehw046.
  8. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med, 2015 Apr 16, 372(16): 1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.